SLC22A1 and ovarian carcinoma: Nevertheless, a recent report by Segal et al. [79] has indicated that OCT1 is expressed in multiple ovarian cancer cell lines, and that siRNA-mediated knockdown of OCT1 expression attenuated the ability of metformin (0–10 mM) to inhibit their survival.